WOUNDCHEK™ Laboratories – Leaders and Innovators in Wound Diagnostics under New Ownership

GARGRAVE, England--()--WOUNDCHEK™ Laboratories announced today that it has successfully secured new financing to take the business forward. As part of the deal ownership of WOUNDCHEK™ Laboratories has transferred from One Equity Partners (OEP) to the newly formed WOUNDCHEK™ Laboratories Holdings Inc., which is owned by several external investors and company management.

Jack Wilkens, CEO and president of WOUNDCHEK™ Laboratories, commented: “Our vision is to provide clinicians with better, accurate, timely, actionable, and easy to access information, leading to improved therapeutic outcomes and more cost effective care through point of care wound diagnostics. We are actively working on our second wound diagnostic product for ‘active infection’. Our first two products address critical questions, identified by clinical experts as pieces of diagnostic information needed to direct treatment pathways in the majority of chronic wounds: ‘Does the wound have elevated protease activity?’ and ‘Is there an active infection?”

WOUNDCHEK™ Protease Status is the world’s first point of care test to detect elevated protease activity (EPA) in chronic wounds and was launched in 2012 in Europe, the Middle East, and South Africa. A chronic wound with EPA has a 90% probability it won’t heal without appropriate protease modulating intervention1. Recent studies have further shown that chronic wounds with EPA carry a significantly higher probability of graft failure than chronic wounds with low protease activity2,3. Clinical experts agree that testing chronic wounds for EPA can help better target advanced therapies and interventions4,5.

- ENDS -

Disclaimer

WOUNDCHEK™ Protease Status is not currently cleared by FDA for sale within the US market.

1. Serena, T. et al., Protease activity levels associated with healing status of chronic wounds, Wounds UK 2011

2. Duteille, F., Evaluation of the use of point-of-care test for proteases to identify patients with increased risk of skin graft failure, EWMA 2013

3. Uccioli, L. et al., Matrix Metalloproteinases levels influence the integration of dermal grafts in diabetic foot ulcers., DFCON 2014

4. International Consensus. The role of proteases in wound diagnostics. An expert working group review. London: Wounds International, 2011

5. Strohal, R. et al., The Role of a point-of-care protease test in wound diagnostics, Wund Management 2012

Contacts

VSPR
Vicky Stoakes
07747 534 519
Vicky@vs-pr.com.

Release Summary

WOUNDCHEK™ Laboratories secures new financing and announces the newly formed WOUNDCHEK™ Laboratories Holdings Inc.

Sharing

Contacts

VSPR
Vicky Stoakes
07747 534 519
Vicky@vs-pr.com.